Cover Image
市場調查報告書

多發性骨髓瘤(卡勒氏病):全球臨床實驗趨勢

Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H2, 2016

出版商 GlobalData 商品編碼 225555
出版日期 內容資訊 英文 1665 Pages
訂單完成後即時交付
價格
Back to Top
多發性骨髓瘤(卡勒氏病):全球臨床實驗趨勢 Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H2, 2016
出版日期: 2016年08月30日 內容資訊: 英文 1665 Pages
簡介

本報告提供多發性骨髓瘤(卡勒氏病)相關之臨床研究最新趨勢分析,以疾病概要為首,提供您G7各國·E7各國的臨床實驗狀況,各地區、各階段的進行狀況,有潛力的贊助商,各企業及研究機關的研究進行狀況,並彙整有潛力的藥劑比較等資訊。

本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 前五名國家的臨床實驗數量; 亞太地區
    • 前五名國家的臨床實驗數量; 歐洲
    • 主要國家的臨床實驗數量; 北美
    • 前五名國家的臨床實驗數量; 中東/非洲地區
    • 前五名國家的臨床實驗數量; 中南美

G7各國的臨床實驗數量:多發性骨髓瘤(卡勒氏病)臨床實驗數量上腫瘤臨床實驗數量比率

各期臨床實驗數量: G7各國

G7各國的臨床實驗數量:各期

E7各國的臨床實驗數量:多發性骨髓瘤(卡勒氏病)臨床實驗數量上腫瘤臨床實驗數量比率

各期臨床實驗數量: E7各國

E7各國的臨床實驗數量:各期

各期臨床實驗數量

  • 各期的進展中臨床實驗數量

各進展狀況臨床實驗數量

評估項目別臨床實驗數量

一定期間所採用的受驗人數

贊助商類別的臨床實驗數量

有潛力的贊助商

臨床實驗主要參加企業 - 多發性骨髓瘤(卡勒氏病)治療藥

有潛力的藥劑

最新臨床實驗新聞:多發性骨髓瘤(卡勒氏病)

臨床實驗簡介的基本資料

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC3734CTIDB

GlobalData's clinical trial report, "Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H2, 2016" provides an overview of Multiple Myeloma (Kahler Disease) clinical trials scenario. This report provides top line data relating to the clinical trials on Multiple Myeloma (Kahler Disease). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials
  • Prominent Drugs
    • Latest Clinical Trials News on Multiple Myeloma (Kahler Disease)
      • Sep 14, 2016: GlycoMimetics Doses First Patient in Phase 1 Clinical Trial of Drug Candidate GMI-1271 for Multiple Myeloma
      • Sep 09, 2016: Celyad completes the NKR-2 Phase I trial with successful safety follow-up of the fourth dose level
      • Sep 06, 2016: Karyopharm Reports Positive Top-Line Phase 2b STORM Results and Reviews the Planned Development Path for Selinexor in Multiple Myeloma
      • Aug 30, 2016: Karyopharm to Host Conference Call with Update on Multiple Myeloma Plans
      • Aug 25, 2016: Data from Phase III CASTOR Study of Daratumumab Published in The New England Journal of Medicine
      • Aug 19, 2016: Additional two centers started screening of Multiple Myeloma patients in OV's APO010 Study
      • Jul 25, 2016: Daratumumab (DARZALEX) Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Use in Combination with Standard of Care Regimens for Patients with Multiple Myeloma
      • Jul 13, 2016: Immunotherapy benefits relapsed stem cell transplant recipients
      • Jul 07, 2016: Janssen and Johnson & Johnson to Provide Webcast Presentation on Phase 3 data for DARZALEX (daratumumab) and the Janssen Immuno-oncology Strategy and Portfolio
  • Clinical Trial Profile Snapshots
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Region, 2016*
  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Europe, Top Five Countries, 2016*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, North America, Top Countries, 2016*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016*
  • Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials, G7 Countries (%), 2016*
  • Multiple Myeloma (Kahler Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Multiple Myeloma (Kahler Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials, E7 Countries (%), 2016*
  • Multiple Myeloma (Kahler Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Multiple Myeloma (Kahler Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Phase, 2016*
  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials In Progress by Phase 2016*
  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Multiple Myeloma (Kahler Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*

List of Figures

  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Region (%), 2016*
  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, North America, Top Countries (%), 2016*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016*
  • Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials, G7 Countries (%), 2016*
  • Multiple Myeloma (Kahler Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Multiple Myeloma (Kahler Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials, E7 Countries (%), 2016*
  • Multiple Myeloma (Kahler Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Multiple Myeloma (Kahler Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Phase (%), 2016*
  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials In Progress by Phase, 2016*
  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Multiple Myeloma (Kahler Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*
  • GlobalData Methodology
Back to Top